Literature DB >> 27727026

Best practice for perioperative management of patients with cytoreductive surgery and HIPEC.

C Raspé1, L Flöther2, R Schneider3, M Bucher2, P Piso4.   

Abstract

Due to the significantly improved outcome and quality of life of patients with different tumor entities after cytoreductive surgery (CRS) and HIPEC, there is an increasing number of centers performing CRS and HIPEC procedures. As this procedure is technically challenging with potential high morbidity and mortality, respectively, institutional experience also in the anesthetic and intensive care departments is essential for optimal treatment and prevention of adverse events. Clinical pathways have to be developed to achieve also good results in more comorbid patients with border line indications and extensive surgical procedures. The anesthesiologist has deal with relevant fluid, blood and protein losses, increased intraabdominal pressure, systemic hypo-/hyperthermia, and increased metabolic rate in patients undergoing cytoreductive surgery with HIPEC. It is of utmost importance to maintain or restore an adequate volume by aggressive substitution of intravenous fluids, which counteracts the increased fluid loss and venous capacitance during this procedure. Supplementary thoracic epidural analgesia, non-invasive ventilation, and physiotherapy are recommended to guarantee adequate pain therapy and postoperative extubation as well as fast-track concepts. Advanced hemodynamic monitoring is essential to help the anesthesiologist picking up information about the real-time fluid status of the patient. Preoperative preconditioning is mandatory in patients scheduled for HIPEC surgery and will result in improved outcome. Postoperatively, volume status optimization, early nutritional support, sufficient anticoagulation, and point of care coagulation management are essential. This is an extensive update on all relevant topics for anesthetists and intensivists dealing with CRS and HIPEC.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Coagulation; Cytoreductive surgery (CRS); Fluid therapy; Hemodynamic management; Hyperthermic intraoperative chemotherapy (HIPEC); Pain control

Mesh:

Substances:

Year:  2016        PMID: 27727026     DOI: 10.1016/j.ejso.2016.09.008

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  28 in total

1.  The effects of platelet-rich-plasma gel application to the colonic anastomosis in hyperthermic intraperitoneal chemotherapy: An experimental rat model.

Authors:  Sonmez Ocak; Omer F Buk; Bugra Genc; Bahattin Avcı; Hatice O Uzuner; Salih B Gundogdu
Journal:  Int Wound J       Date:  2019-08-25       Impact factor: 3.315

2.  Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.

Authors:  Jason B Liu; Darryl Schuitevoerder; Charles C Vining; Yaniv Berger; Kiran K Turaga; Oliver S Eng
Journal:  Ann Surg Oncol       Date:  2020-07-29       Impact factor: 5.344

3.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

Review 4.  Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis.

Authors:  Mikkel Lundbech; Andreas Engel Krag; Lene Hjerrild Iversen; Anne-Mette Hvas
Journal:  Int J Colorectal Dis       Date:  2021-10-09       Impact factor: 2.571

5.  Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.

Authors:  Doralina L Anghelescu; Christina-Lin Brown; Andrew J Murphy; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Zachary E Stiles; Michael W Bishop; Luke Douthitt; Jeremiah L Deneve
Journal:  Ann Surg Oncol       Date:  2018-10-23       Impact factor: 5.344

6.  Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.

Authors:  Alberto Di Leo; Arianna Corvasce; Jacopo Weindelmayer; Elena Jane Mason; Francesco Casella; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2020-05-14

7.  Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC.

Authors:  Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt
Journal:  J Gastrointest Surg       Date:  2018-04-30       Impact factor: 3.452

8.  Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  June S Peng; Jessica LaPiano; Katy Wang; Kristopher Attwood; Joseph J Skitzki; John M Kane; Valerie A Francescutti
Journal:  Ann Surg Oncol       Date:  2021-08-12       Impact factor: 5.344

Review 9.  [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].

Authors:  Felix Gronau; Maximilian Jara; Linda Feldbrügge; Vincent Wolf; Alan Oeff; Beate Rau
Journal:  Chirurg       Date:  2021-02-23       Impact factor: 0.955

10.  A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.

Authors:  Rachel M Lee; Adriana C Gamboa; Michael K Turgeon; Mohammad Y Zaidi; Charles Kimbrough; Jennifer Leiting; Travis Grotz; Andrew J Lee; Keith Fournier; Benjamin Powers; Sean Dineen; Joel M Baumgartner; Jula Veerapong; Harveshp Mogal; Callisia Clarke; Gregory Wilson; Sameer Patel; Ryan Hendrix; Laura Lambert; Courtney Pokrzywa; Daniel E Abbott; Christopher J LaRocca; Mustafa Raoof; Jonathan Greer; Fabian M Johnston; Charles A Staley; Jordan M Cloyd; Shishir K Maithel; Maria C Russell
Journal:  J Surg Oncol       Date:  2020-10-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.